肿瘤体积、HPV状态、干细胞标志物与缺氧基因特征可识别HNSCC放疗化疗效佳亚组
该多中心回顾性研究纳入158例接受根治性放疗化疗的局部晚期口腔、口咽或下咽鳞状细胞癌患者,分析肿瘤体积、HPV状态、癌症干细胞标志物表达及缺氧基因特征对疗效的影响,主要终点为局部区域控制。单因素分析显示肿瘤体积、p16过表达及SLC3A2、CD44蛋白表达与局部区域控制显著相关,多因素分析证实肿瘤体积、SLC3A2表达和15基因缺氧特征为独立相关因素;纳入CD44蛋白表达和p16过表达可显著提高2年局部区域控制的预测能力。
要点
- 肿瘤体积、p16过表达及SLC3A2、CD44蛋白表达与局部区域控制显著相关。
- 多因素分析中肿瘤体积、SLC3A2表达和15基因缺氧特征为独立相关因素。
- 联合CD44蛋白表达和p16过表达可提高2年局部区域控制的预测能力。
核心结论
- 肿瘤体积、HPV状态、癌症干细胞标志物表达和缺氧基因特征可作为接受根治性放疗化疗的局部晚期头颈鳞状细胞癌患者的潜在预后生物标志物。
- 研究支持将个体肿瘤体积常规纳入生物标志物研究,且多标志物组合优于单一参数。
研究设计与样本
- 德国癌症联盟放射肿瘤学组(DKTK-ROG)多中心回顾性研究,纳入158例在六个DKTK合作中心接受根治性放疗化疗的局部晚期口腔、口咽或下咽头颈鳞状细胞癌患者。
- 分析肿瘤体积、HPV DNA、p16过表达、p53表达、癌症干细胞标志物表达及缺氧相关基因特征对疗效的影响,主要终点为局部区域控制(LRC)。
主要发现
- 单因素Cox回归显示肿瘤体积、p16过表达、SLC3A2和CD44蛋白表达对LRC有显著影响。
- 肿瘤缺氧分类仅在小肿瘤中显示显著影响。
- 多因素分析显示肿瘤体积、SLC3A2表达和15基因缺氧特征与LRC独立相关;CD44蛋白因阴性组无事件未纳入分析。
- Logistic模型显示纳入CD44蛋白表达和p16过表达后,预测2年LRC的能力较仅用肿瘤体积的模型显著提高。
临床怎么用
- 对局部晚期头颈鳞状细胞癌接受根治性放疗化疗的患者,可综合评估肿瘤体积、HPV状态、干细胞标志物和缺氧基因特征以辅助预后分层。
- 生物标志物研究应纳入个体肿瘤体积,并优先采用多标志物组合而非单一指标。
局限性
- 为回顾性研究,样本量158例,结论需前瞻性验证。
- CD44蛋白多因素分析因阴性组无事件未能完成。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the impact of the tumour volume, HPV status, cancer stem cell (CSC) marker expression and hypoxia gene signatures, as potential markers of radiobiological mechanisms of radioresistance, in a contemporary cohort of patients with locally advanced head and neck squamous cell carcinoma (HNSCC), who received primary radiochemotherapy (RCTx). MATERIALS AND METHODS: For 158 patients with locally advanced HNSCC of the oral cavity, oropharynx or hypopharynx who were treated at six DKTK partner sites, the impact of tumour volume, HPV DNA, p16 overexpression, p53 expression, CSC marker expression and hypoxia-associated gene signatures on outcome of primary RCTx was retrospectively analyzed. The primary endpoint of this study was loco-regional control (LRC). RESULTS: Univariate Cox regression revealed a significant impact of tumour volume, p16 overexpression, and SLC3A2 and CD44 protein expression on LRC. The tumour hypoxia classification showed a significant impact only for small tumours. In multivariate analyses an independent correlation of tumour volume, SLC3A2 expression, and the 15-gene hypoxia signature with LRC was identified (CD44 protein n/a because of no event in the CD44-negative group). Logistic modelling showed that inclusion of CD44 protein expression and p16 overexpression significantly improved the performance to predict LRC at 2years compared to the model with tumour volume alone. CONCLUSIONS: Tumour volume, HPV status, CSC marker expression and hypoxia gene signatures are potential prognostic biomarkers for patients with locally advanced HNSCC, who were treated by primary RCTx. The study also supports that the individual tumour volumes should generally be included in biomarker studies and that panels of biomarkers are superior to individual parameters.
引用
- Linge A, Lohaus F, Löck S, et al. HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Radiother Oncol. 2016. PMID: 27913065. doi:10.1016/j.radonc.2016.11.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。